(Z)-4-HydroxytamoxifenER modulator, potent and selective CAS# 68047-06-3 |
2D Structure
- Fulvestrant
Catalog No.:BCC1081
CAS No.:129453-61-8
- Bazedoxifene
Catalog No.:BCC1411
CAS No.:198481-32-2
- Bazedoxifene acetate
Catalog No.:BCC1412
CAS No.:198481-33-3
- (E)-2-Decenoic acid
Catalog No.:BCC1292
CAS No.:334-49-6
- Toremifene
Catalog No.:BCC2010
CAS No.:89778-26-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 68047-06-3 | SDF | Download SDF |
PubChem ID | 5284643 | Appearance | Powder |
Formula | C26H29NO2 | M.Wt | 387.51 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | 4-OH-TAM;4-Hydroxytamoxifen; Afimoxifene; Hydroxytamoxifen; Tamogel; 4-Monohydroxytamoxifen | ||
Solubility | DMSO : ≥ 28 mg/mL (72.26 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol | ||
SMILES | CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=C(C=C3)O | ||
Standard InChIKey | DODQJNMQWMSYGS-QPLCGJKRSA-N | ||
Standard InChI | InChI=1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Estrogen receptor antagonist. Tamoxifen metabolite; exhibits greater potency than the parent compound. Chemotherapeutic agent. Also activates intein-linked inactive Cas9, reducing off-target CRISPR-mediated gene editing; system has ~25-fold higher specificity than wtCas9. |
(Z)-4-Hydroxytamoxifen Dilution Calculator
(Z)-4-Hydroxytamoxifen Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5806 mL | 12.9029 mL | 25.8058 mL | 51.6116 mL | 64.5145 mL |
5 mM | 0.5161 mL | 2.5806 mL | 5.1612 mL | 10.3223 mL | 12.9029 mL |
10 mM | 0.2581 mL | 1.2903 mL | 2.5806 mL | 5.1612 mL | 6.4514 mL |
50 mM | 0.0516 mL | 0.2581 mL | 0.5161 mL | 1.0322 mL | 1.2903 mL |
100 mM | 0.0258 mL | 0.129 mL | 0.2581 mL | 0.5161 mL | 0.6451 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Estrogen receptors (ER) are members of the superfamily of ligand-modulated nuclear receptors that mediate the actions of steroid hormones, vitamin D, retinoids, and thyroid hormones. ER is activated in vivo when bound by naturally occurring estrogens such as 17α-estradiol. In addition to regulating these physiological processes, estrogen also plays a central role in stimulating breast cancer growth. (Z)-Tamoxifen is a first generation selective ER modulators that is currently approved by the FDA and is widely used to treat estrogen-dependent breast cancers. Its active metabolite, (Z)-4-Hydroxytamoxifen, is a potent estrogen receptor modulator.
In vitro: (Z)-4-hydroxytamoxifen binds to ER with 8-fold higher affinity than tamoxifen. It was found that only the Z isomer has the required antiestrogenic activity; the (E)-4-hydroxytamoxifen has only about 5% of its affinity for the ER [1].
In vivo: The antioestrogenic activities of (Z)-4-hydroxytamoxifen and tamoxifen were determined after oral administration. (Z)-4-hydroxytamoxifen was administered to groups of immature rats which also received s.c. injections of 0-2 μg oestradiol. Both compounds produced a dose-related decrease in uterine wet weight when compared with the oestradiol-treated controls. At a dose of 1 μg/day, the antiuterotrophic effects of (Z)-4-hydroxytamoxifen and tamoxifen were not significantly different but at 5μg/day, (Z)-4-hydroxytamoxifen was more active (P < 0.01). (Z)-4-hydroxytamoxifen therefore appears to retain its potent antioestrogenic activity after oral administration [2].
Clinical trial: Up to now, (Z)-4-Hydroxytamoxifen is still in the preclinical development stage.
Reference:
[1] Donna D. Yu and Barry M. Forman. Simple and Efficient Production of (Z)-4-Hydroxytamoxifen, a Potent Estrogen Receptor Modulator. J. Org. Chem. 2003, 68, 9489-9491
[2] Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977 Nov;75(2):305-16.
- Carbadox
Catalog No.:BCC3744
CAS No.:6804-07-5
- Pulsatilla saponin D
Catalog No.:BCN8526
CAS No.:68027-15-6
- Pulsatilla saponin H
Catalog No.:BCN8181
CAS No.:68027-14-5
- Magnocurarine
Catalog No.:BCN3839
CAS No.:6801-40-7
- Hydroxyprogesterone
Catalog No.:BCC8996
CAS No.:68-96-2
- Ac-Pro-OH
Catalog No.:BCC3017
CAS No.:68-95-1
- Hypoxanthine
Catalog No.:BCC5324
CAS No.:68-94-0
- Metamizole sodium
Catalog No.:BCC9024
CAS No.:68-89-3
- Hydroxyzine
Catalog No.:BCC5209
CAS No.:68-88-2
- Sulfadiazine
Catalog No.:BCC3859
CAS No.:68-35-9
- Vitamin A
Catalog No.:BCN8349
CAS No.:68-26-8
- Norethindrone
Catalog No.:BCC4811
CAS No.:68-22-4
- Escin
Catalog No.:BCC8323
CAS No.:6805-41-0
- Platyconic acid A
Catalog No.:BCN3239
CAS No.:68051-23-0
- EMPA
Catalog No.:BCC6226
CAS No.:680590-49-2
- Megastigm-7-ene-3,5,6,9-tetraol
Catalog No.:BCN5169
CAS No.:680617-50-9
- Trifolirhizin
Catalog No.:BCN4237
CAS No.:6807-83-6
- Norfloxacin hydrochloride
Catalog No.:BCC4230
CAS No.:68077-27-0
- Boc-Phe(4-Cl)-OH
Catalog No.:BCC3172
CAS No.:68090-88-0
- 4',5,7-Trihydroxy-6-prenylflavone
Catalog No.:BCN4238
CAS No.:68097-13-2
- Bepridil hydrochloride
Catalog No.:BCC7864
CAS No.:68099-86-5
- 13-Dehydroxyindaconintine
Catalog No.:BCN8403
CAS No.:681-18-9
- AICAR phosphate
Catalog No.:BCC4220
CAS No.:681006-28-0
- JNJ-1661010
Catalog No.:BCC2315
CAS No.:681136-29-8
Synthesis of (Z)-4-hydroxytamoxifen and (Z)-2-[4-[1-(p-hydroxyphenyl)-2-phenyl]-1butenyl]phenoxyacetic acid.[Pubmed:12076167]
J Org Chem. 2002 Jun 28;67(13):4608-11.
The synthesis of (Z)-4-Hydroxytamoxifen and (Z)-2-[4-[1-(p-hydroxyphenyl)-2-phenyl]-1-butenyl]phenoxyacetic acid was accomplished using a McMurry reaction as the key step. The perfluorotolyl derivatives of the McMurry products enabled the separation of the minor undesirable geometrical isomer. The methodology proceeds without E,Z isomerization, employs a very mild final debenzylation step compatible with a large array of functional groups, and can be applied to the generation of a variety of 4-hydroxytamoxifen analogues.
Simple and efficient production of (Z)-4-hydroxytamoxifen, a potent estrogen receptor modulator.[Pubmed:14629178]
J Org Chem. 2003 Nov 28;68(24):9489-91.
A McMurry coupling reaction and selective crystallization were used to develop a simple and efficient two-step synthesis of (Z)-4-Hydroxytamoxifen (2a). This compound is an active metabolite of tamoxifen, a selective estrogen receptor (ER) modulator widely used to treat breast cancer. The synthesis employed 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene (1) as a useful building block.
Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates.[Pubmed:10021916]
Bioorg Med Chem Lett. 1999 Jan 18;9(2):141-4.
We report the development of (E)- and (Z)-4-Hydroxytamoxifen sulfamates as estrone sulfatase inhibitors, potential therapeutic agents for the treatment of breast cancer. Both compounds competitively inhibit estrone sulfatase isolated from rat liver with apparent Ki of 35.9 microM for (E)-4-hydroxytamoxifen sulfamate and an apparent Ki of > 500 microM for the (Z) isomer.
Small molecule-triggered Cas9 protein with improved genome-editing specificity.[Pubmed:25848930]
Nat Chem Biol. 2015 May;11(5):316-8.
Directly modulating the activity of genome-editing proteins has the potential to increase their specificity by reducing activity following target locus modification. We developed Cas9 nucleases that are activated by the presence of a cell-permeable small molecule by inserting an evolved 4-hydroxytamoxifen-responsive intein at specific positions in Cas9. In human cells, conditionally active Cas9s modify target genomic sites with up to 25-fold higher specificity than wild-type Cas9.
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.[Pubmed:15159443]
J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
We performed comprehensive kinetic, inhibition, and correlation analyses in human liver microsomes and experiments in expressed human cytochromes P450 (P450s) to identify primary and secondary metabolic routes of tamoxifen (TAM) and the P450s catalyzing these reactions at therapeutically relevant concentrations. N-Desmethyl-TAM formation catalyzed by CYP3A4/5 was quantitatively the major primary metabolite of TAM; 4-hydroxy-TAM formation catalyzed by CYP2D6 (and other P450s) represents a minor route. Other minor primary metabolites include alpha -, 3-, and 4'-hydroxyTAM and one unidentified metabolite (M-I) and were primarily catalyzed by CYP3A4, CYP3A5, CYP2B6/2C19, and CYP3A4, respectively. TAM secondary metabolism was examined using N-desmethyl- and 4-hydroxy-TAM as intermediate substrates. N-Desmethyl-TAM was predominantly biotransformed to alpha-hydroxy N-desmethyl-, N-didesmethyl-, and 4-hydroxy N-desmethyl-TAM (endoxifen), whereas 4-hydroxy-TAM was converted to 3,4-dihydroxyTAM and endoxifen. Except for the biotransformation of N-desmethyl-TAM to endoxifen, which was exclusively catalyzed by CYP2D6, all other routes of N-desmethyl- and 4-hydroxy-TAM biotransformation were catalyzed predominantly by the CYP3A subfamily. TAM and its primary metabolites undergo extensive oxidation, principally by CYP3A and CYP2D6 to metabolites that exhibit a range of pharmacological effects. Variable activity of these P450s, brought about by genetic polymorphisms and drug interactions, may alter the balance of TAM effects in vivo.
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.[Pubmed:591813]
J Endocrinol. 1977 Nov;75(2):305-16.
The oestrogenic and antioestrogenic properties of tamoxifen and its monohydroxylated (monohydroxytamoxifen) and dihydroxylated (dihydroxytamoxifen) metabolites have been investigated in the immature rat. Whether administered orally or subcutaneously, monohydroxytamoxifen was more active than tamoxifen as an antioestrogen. Dihydroxytamoxifen was less active than tamoxifen as an antioestrogen, but this derivative alone was unable to induce a uterotrophic response. Both metabolites of tamoxifen were potent inhibitors of the binding of [3H]oestradiol to oestrogen receptors in vitro. It is possible that the metabolites play a supportive role in the antioestrogenic activity of tamoxifen. The potent activity of monohydroxytamoxifen in vivo and in vitro suggests that this compound could be an important new tool for the subcellular investigation of oestrogenic and antioestrogenic events.